Desperate hope: one patient gets custom immune cells for rare cancer
NCT ID NCT06789081
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a one-of-a-kind cell therapy called GCAR1 in a single patient with advanced alveolar soft part sarcoma, a rare cancer that has spread. The therapy uses the patient's own immune cells, modified to recognize and attack cancer cells that carry a specific protein (GPNMB). The main goal is to see if the tumor shrinks after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GCAR1 (a personalized cell therapy made from the patient's own immune cells, engineered to target cancer cells)
What this could lead to
If it works, this could point toward a new treatment option for alveolar soft part sarcoma, a rare cancer with few alternatives.
What could go wrong
This is an extremely early trial with only one patient, so results may not apply to others. The therapy is experimental and may not shrink the tumor or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALVEOLAR SOFT PART SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Arthur J.E. Child Comprehensive Cancer Centre
Calgary, Alberta, T2N 5G2, Canada